+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antithrombogenic Heparin Coating Market by End Use (Cardiovascular Stents, Catheters, Extracorporeal Circuits), Coating Type (Biodegradable, Permanent), Technology, End User - Global Forecast 2025-2030- Product Image
Antithrombogenic Heparin Coating Market by End Use (Cardiovascular Stents, Catheters, Extracorporeal Circuits), Coating Type (Biodegradable, Permanent), Technology, End User - Global Forecast 2025-2030- Product Image
New

Antithrombogenic Heparin Coating Market by End Use (Cardiovascular Stents, Catheters, Extracorporeal Circuits), Coating Type (Biodegradable, Permanent), Technology, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6149869
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Comprehensive Overview of Heparin Antithrombogenic Coating Principles Innovations and Clinical Significance Driving Advanced Medical Device Performance

Heparin-based antithrombogenic coatings have emerged as a cornerstone technology in advancing the performance and safety of blood-contacting medical devices. By imparting a bioactive surface that actively modulates coagulation pathways, these coatings reduce the risk of thrombosis and enhance the biocompatibility of critical interventions. Historically, surface treatments relied on passive barriers to isolate blood from device materials, but the evolution toward dynamic antithrombogenic interfaces represents a paradigm shift. This approach leverages the inherent anticoagulant properties of heparin, anchored through chemical or physical methods, to maintain endothelial function and mitigate inflammatory responses.

Examining the Critical Shifts in Technology Regulation and Clinical Practice Shaping the Future of Heparin Coating Applications in Cardiovascular Therapies

The landscape of antithrombogenic heparin coatings is undergoing a series of transformative shifts driven by breakthroughs in material science, emerging regulatory standards, and evolving clinical practices. Innovations in covalent bonding techniques have enabled stronger, longer-lasting integration of heparin molecules with device substrates, thereby extending the functional lifespan of coated implants and catheters. Meanwhile, the rise of biodegradable delivery systems that gradually release heparin in response to physiological triggers is redefining how sustained anticoagulant activity is achieved within the body. As medical device regulators increasingly emphasize patient safety and performance validation, manufacturers are adopting rigorous testing protocols that align with updated ISO guidelines and regional compliance requirements. This regulatory impetus is complemented by clinical trends favoring minimally invasive procedures, which demand thinner, more durable coatings to accommodate smaller device profiles. Consequently, design priorities have shifted from simple thromboresistance to multifunctional surfaces that can support endothelialization, reduce microbial adhesion, and deliver targeted therapeutic agents. These converging forces are shaping a new generation of antithrombogenic solutions that not only prevent clot formation but also actively contribute to long-term device integration and patient outcomes.

Analyzing the Comprehensive Economic Effects of United States Tariff Adjustments Scheduled for 2025 on Heparin Coating Raw Materials and Supply Chains

The introduction of revised United States tariffs effective in 2025 has created multifaceted economic effects on the supply chain and production costs of heparin antithrombogenic coatings. Manufacturers relying on raw heparin extracted from porcine sources are now contending with elevated import duties that have raised procurement expenses and prompted a reassessment of global sourcing strategies. In response, some industry actors have accelerated investments in synthetic heparin analogs and recombinant production platforms to reduce dependency on traditional feedstock and buffer against tariff volatility. The tariff adjustments also ripple through auxiliary raw materials-such as specialty lipids, polymer substrates, and crosslinking agents-necessitating a closer examination of vendor contracts and regional manufacturing footprints.

Insightful Analysis of Market Segmentation by End Use Coating Type Technology and End User to Uncover Key Growth Drivers and Adoption Trends

A detailed segmentation analysis reveals distinct usage patterns and innovation trajectories across multiple dimensions of the antithrombogenic heparin coating market. In cardiovascular interventions, stents continue to be a primary application, while catheters span urinary and vascular uses, the latter of which include diagnostic probes and therapeutic delivery platforms. Extracorporeal circuits designed for cardiopulmonary bypass and hemodialysis demand coatings that withstand prolonged blood exposure, and heart valve implants-both bioprosthetic and mechanical-require durable antithrombogenic barriers. Additionally, vascular grafts, categorized into biological autologous and homograft materials as well as synthetic constructs composed of Dacron or PTFE, are increasingly coated with heparin to extend graft patency. From a formulation perspective, permanent coatings provide continuous anticoagulant action, while biodegradable options such as heparin lipid conjugates and polymer blends offer controlled elution profiles. Underpinning these coating types are technological approaches that range from biofunctionalization and covalent bonding to simpler physical adsorption methods. The final dimension of segmentation highlights end users, where ambulatory surgical centers leverage shorter-term interventions, hospitals manage complex cardiovascular cases, and research laboratories pilot next-generation coating chemistries. Together, these segmentation insights articulate a nuanced portrait of the current landscape and identify specific segments poised for accelerated adoption.

Regional Dynamics and Growth Catalysts in the Americas Europe Middle East Africa and Asia Pacific Markets for Heparin Antithrombogenic Coatings

Regional market performance exhibits marked variations shaped by differing healthcare infrastructures, reimbursement environments, and regulatory landscapes. In the Americas, robust clinical trial activity and widespread adoption of advanced interventional cardiology technologies create a fertile ground for antithrombogenic coatings, with leading hospitals and cardiac centers driving continuous innovation. Shifts in reimbursement policies toward value-based care further incentivize the use of coatings that demonstrably reduce post-operative complications and hospital readmissions. Across Europe, the Middle East, and Africa, harmonized regulatory frameworks facilitate cross-border commercialization, while stringent safety standards ensure high product quality. Emerging markets within this region have begun to align with broader European guidelines, accelerating access to novel coatings, and expanding opportunities for manufacturers willing to navigate complex approval pathways. In the Asia Pacific arena, rapid growth is fueled by increasing cardiovascular disease prevalence, government investments in healthcare infrastructure, and partnerships between domestic enterprises and international medical device firms. Local production hubs are integrating heparin coating capabilities into existing manufacturing platforms, supported by Chinese and Japanese research institutions that drive formulation advancements. Together, these regional dynamics underscore the importance of tailored market strategies that address unique regulatory requirements, reimbursement structures, and clinical priorities.

Strategic Competitive Landscape Review Highlighting Leading Companies Partnerships Innovations and Market Positioning in the Heparin Coating Sector

The competitive landscape features a blend of established medical device manufacturers and specialized coating technology firms forging strategic alliances to drive innovation. Leading global players have diversified their portfolios by acquiring niche coating developers and forging research collaborations with academic institutions. At the same time, emerging companies are focusing on proprietary heparin conjugation chemistries, targeted delivery mechanisms, and expanded patent portfolios. Firms with extensive clinical trial networks are better positioned to validate new formulations, while those controlling integrated production capabilities can accelerate time-to-market for advanced coatings. In parallel, partnerships between device OEMs and contract development organizations enable flexible scale-up of coating processes, meeting the varied demands of capital-intensive applications such as extracorporeal circuits and heart valve implants. Strategic mergers have also reshaped market dynamics, consolidating expertise in polymer science, surface modification, and anticoagulant technologies. These evolving alliances underscore the importance of collaborative ecosystems that blend device design, coating chemistry, and regulatory know-how to deliver next-generation antithrombogenic solutions.

Actionable Strategic Recommendations for Industry Leaders to Drive Innovation Supply Chain Resilience and Regulatory Compliance in Heparin Coatings

To drive sustained leadership in the antithrombogenic heparin coating field, industry participants should prioritize a multifaceted approach that aligns technological innovation with operational excellence. Investment in advanced biodegradable coating platforms can generate differentiated product offerings and address growing demand for controlled release profiles. Concurrently, diversifying raw material sourcing through partnerships with synthetic heparin producers will mitigate tariff exposure and supply chain disruptions. Organizations should also implement robust regulatory intelligence frameworks to anticipate standard revisions and streamline global approvals. On the clinical front, engaging early with key opinion leaders and conducting real-world evidence studies will validate performance claims and support favorable reimbursement. Collaboration across the value chain-including device OEMs, contract manufacturers, and research institutions-can accelerate process optimization and reduce development cycle times. Finally, targeted expansion into high-growth regional markets should be underpinned by localized commercialization strategies, ensuring alignment with healthcare provider needs, procurement practices, and patient access pathways.

Detailed Explanation of Research Methodology Incorporating Primary Interviews Secondary Data and Rigorous Validation for Comprehensive Market Analysis

The research foundation incorporates a blend of primary and secondary methodologies to ensure a holistic and validated market analysis. Primary insights were gathered through structured interviews with cardiovascular surgeons, interventional cardiologists, device engineers, and regulatory specialists across key regions. Detailed discussions with procurement managers at leading hospitals and ambulatory surgical centers provided real-world perspectives on adoption drivers and decision criteria. Secondary research encompassed peer-reviewed literature, regulatory filing databases, patent landscapes, and clinical trial repositories to map technology milestones and approval timelines. Market dynamics were further informed by an in-depth review of corporate investor presentations, annual reports, and industry conference proceedings. Data triangulation was employed to reconcile discrepancies between sources, while an expert panel conducted iterative validation workshops to refine conclusions. This rigorous methodology ensures that the analysis remains both comprehensive and grounded in verifiable evidence, offering stakeholders actionable insights and strategic clarity.

Synthesis of Key Insights and Strategic Imperatives Summarizing the Critical Findings on Heparin Antithrombogenic Coatings Landscape and Future Outlook

This executive summary has distilled the pivotal themes shaping the antithrombogenic heparin coating market, from material science breakthroughs to regulatory shifts and regional growth dynamics. Segmentation insights reveal a diverse application landscape spanning stents, catheters, extracorporeal circuits, heart valves, and vascular grafts, each benefiting from specialized coating formulations. Technological trends highlight the rise of biodegradable delivery systems and robust covalent bonding methods that enhance functional longevity. The impact of upcoming tariff changes underscores the importance of supply chain agility and material innovation, while the competitive review indicates a landscape driven by strategic alliances and targeted acquisitions. Regional analysis further demonstrates the need for tailored market entry strategies that account for varying regulatory frameworks, reimbursement models, and clinical priorities. Together, these findings offer a clear roadmap for industry stakeholders seeking to harness emerging opportunities, optimize product portfolios, and achieve sustainable growth in a rapidly evolving environment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End Use
    • Cardiovascular Stents
    • Catheters
      • Urinary Catheters
      • Vascular Catheters
        • Diagnostic Catheters
        • Therapeutic Catheters
    • Extracorporeal Circuits
      • Cardiopulmonary Bypass
      • Hemodialysis
    • Heart Valves
      • Bioprosthetic
      • Mechanical
    • Vascular Grafts
      • Biological
        • Autologous
        • Homograft
      • Synthetic
        • Dacron
        • PTFE
  • Coating Type
    • Biodegradable
      • Heparin Lipid Conjugate
      • Heparin Polymer Blend
    • Permanent
  • Technology
    • Biofunctionalization
    • Covalent Bonding
    • Physical Adsorption
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Research Laboratories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Terumo Corporation
  • B. Braun Melsungen AG
  • W. L. Gore & Associates, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Boston Scientific Corporation
  • Abbott Laboratories
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Asahi Kasei Medical Co., Ltd.
  • Corline Biomedical AB

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growth in bioactive heparin coatings enhancing thromboresistance of cardiovascular devices
5.2. Integration of nanoparticle delivery systems for localized heparin release on stents
5.3. Advances in covalent bonding techniques improving long-term heparin stability on surfaces
5.4. Development of combination antithrombogenic and antimicrobial coatings for medical implants
5.5. Expansion of regulatory approvals for heparin-coated extracorporeal circuits in Europe and Asia
5.6. Cost-effective scalable manufacturing methods for uniform heparin coating applications
5.7. Increase in demand for heparin coatings driven by rising cardiovascular intervention procedures
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antithrombogenic Heparin Coating Market, by End Use
8.1. Introduction
8.2. Cardiovascular Stents
8.3. Catheters
8.3.1. Urinary Catheters
8.3.2. Vascular Catheters
8.3.2.1. Diagnostic Catheters
8.3.2.2. Therapeutic Catheters
8.4. Extracorporeal Circuits
8.4.1. Cardiopulmonary Bypass
8.4.2. Hemodialysis
8.5. Heart Valves
8.5.1. Bioprosthetic
8.5.2. Mechanical
8.6. Vascular Grafts
8.6.1. Biological
8.6.1.1. Autologous
8.6.1.2. Homograft
8.6.2. Synthetic
8.6.2.1. Dacron
8.6.2.2. PTFE
9. Antithrombogenic Heparin Coating Market, by Coating Type
9.1. Introduction
9.2. Biodegradable
9.2.1. Heparin Lipid Conjugate
9.2.2. Heparin Polymer Blend
9.3. Permanent
10. Antithrombogenic Heparin Coating Market, by Technology
10.1. Introduction
10.2. Biofunctionalization
10.3. Covalent Bonding
10.4. Physical Adsorption
11. Antithrombogenic Heparin Coating Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Research Laboratories
12. Americas Antithrombogenic Heparin Coating Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Antithrombogenic Heparin Coating Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Antithrombogenic Heparin Coating Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Terumo Corporation
15.3.2. B. Braun Melsungen AG
15.3.3. W. L. Gore & Associates, Inc.
15.3.4. Fresenius Medical Care AG & Co. KGaA
15.3.5. Boston Scientific Corporation
15.3.6. Abbott Laboratories
15.3.7. MicroPort Scientific Corporation
15.3.8. Nipro Corporation
15.3.9. Asahi Kasei Medical Co., Ltd.
15.3.10. Corline Biomedical AB
16. Research AI17. Research Statistics18. Research Contacts19. Research Articles20. Appendix
List of Figures
FIGURE 1. ANTITHROMBOGENIC HEPARIN COATING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANTITHROMBOGENIC HEPARIN COATING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANTITHROMBOGENIC HEPARIN COATING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANTITHROMBOGENIC HEPARIN COATING MARKET: RESEARCHAI
FIGURE 24. ANTITHROMBOGENIC HEPARIN COATING MARKET: RESEARCHSTATISTICS
FIGURE 25. ANTITHROMBOGENIC HEPARIN COATING MARKET: RESEARCHCONTACTS
FIGURE 26. ANTITHROMBOGENIC HEPARIN COATING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTITHROMBOGENIC HEPARIN COATING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CARDIOVASCULAR STENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CARDIOVASCULAR STENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY URINARY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY URINARY CATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY THERAPEUTIC CATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY THERAPEUTIC CATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CARDIOPULMONARY BYPASS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CARDIOPULMONARY BYPASS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOPROSTHETIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOPROSTHETIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY MECHANICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HOMOGRAFT, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HOMOGRAFT, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY DACRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY DACRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY PTFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY PTFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEPARIN LIPID CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEPARIN LIPID CONJUGATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEPARIN POLYMER BLEND, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEPARIN POLYMER BLEND, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY PERMANENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY PERMANENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOFUNCTIONALIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOFUNCTIONALIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COVALENT BONDING, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COVALENT BONDING, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY PHYSICAL ADSORPTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY PHYSICAL ADSORPTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 143. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 144. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 161. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 162. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 163. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 164. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 165. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. CANADA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY HEART VALVES, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR GRAFTS, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIOLOGICAL, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY SYNTHETIC, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY COATING TYPE, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY BIODEGRADABLE, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 290. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 291. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
TABLE 292. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY CATHETERS, 2025-2030 (USD MILLION)
TABLE 293. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2018-2024 (USD MILLION)
TABLE 294. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY VASCULAR CATHETERS, 2025-2030 (USD MILLION)
TABLE 295. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2018-2024 (USD MILLION)
TABLE 296. GERMANY ANTITHROMBOGENIC HEPARIN COATING MARKET SIZE, BY EXTRACORPOREAL CIRCUITS, 2025-2030 (USD MILLION)
TABLE 297

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antithrombogenic Heparin Coating Market report include:
  • Terumo Corporation
  • B. Braun Melsungen AG
  • W. L. Gore & Associates, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Boston Scientific Corporation
  • Abbott Laboratories
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Asahi Kasei Medical Co., Ltd.
  • Corline Biomedical AB

Related Topics

Related Reports

Medical Heparin Coating Market by Coating Type (Covalent Immobilization, Ionic Binding, Layer Assembly), Application (Blood Collection, Cardiovascular Devices, Extracorporeal Circulation), Technique, End User, Form - Global Forecast 2025-2030 - Product Image

Medical Heparin Coating Market by Coating Type (Covalent Immobilization, Ionic Binding, Layer Assembly), Application (Blood Collection, Cardiovascular Devices, Extracorporeal Circulation), Technique, End User, Form - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Anti-thrombogenic Coatings Market by Application (Catheters, Heart Valves, Stents), Material Type (Heparin, Phosphorylcholine, Polymer), Coating Technique, End-Use Industry - Global Forecast 2025-2030 - Product Image

Anti-thrombogenic Coatings Market by Application (Catheters, Heart Valves, Stents), Material Type (Heparin, Phosphorylcholine, Polymer), Coating Technique, End-Use Industry - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Blood Line for Hemodiafiltration Market by Product Type (Reusable, Single Use), Application (Home Hemodiafiltration, Hospital Hemodiafiltration, Outpatient Clinics), End User, Material, Coating - Global Forecast 2025-2030 - Product Image

Blood Line for Hemodiafiltration Market by Product Type (Reusable, Single Use), Application (Home Hemodiafiltration, Hospital Hemodiafiltration, Outpatient Clinics), End User, Material, Coating - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Heparin Coatings Market by Application (Dialysis Equipment, Heart Lung Machines, Stents), Coating Technology (Covalent Bonding, Layer Layer Assembly, Physical Adsorption), Source, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Heparin Coatings Market by Application (Dialysis Equipment, Heart Lung Machines, Stents), Coating Technology (Covalent Bonding, Layer Layer Assembly, Physical Adsorption), Source, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Heparin Anti-thrombogenic Coating Market by Application (Cardiovascular Stents, Grafts, Orthopedic Implants), Coating Technology (Covalent Bonding, Ionic Adsorption, Layer Layer Assembly), Delivery Method, Product Type, End User - Global Forecast 2025-2030 - Product Image

Heparin Anti-thrombogenic Coating Market by Application (Cardiovascular Stents, Grafts, Orthopedic Implants), Coating Technology (Covalent Bonding, Ionic Adsorption, Layer Layer Assembly), Delivery Method, Product Type, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.